TEsting METformin Against Cognitive Decline in HD

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

June 10, 2025

Study Completion Date

June 10, 2025

Conditions
Huntington Disease
Interventions
DRUG

Metformin

Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)

DRUG

Placebo

425 mg twice daily (initial dose) and 850 twice daily (maximum dose)

Trial Locations (9)

28034

Hospital Universitario Ramón y Cajal, Madrid

33011

Hospital Universitario Central de Asturias, Oviedo

46026

Hospital Universitario y Politécnico La Fe, Valencia

03010

Hospital General Universitario Dr. Balmis, Alicante

03203

Hospital General Universitario de Elche, Elche

07120

Hospital Universitari Son Espases, Palma de Mallorca

08035

Hospital Universitario Mare de Déu de la Mercé, Barcelona

09006

Hospital Universitario Burgos, Burgos

02006

Complejo Hospitalario de Albacete, Albacete

All Listed Sponsors
lead

Instituto de Investigacion Sanitaria La Fe

OTHER